Relmada Therapeutics (RLMD) has had the highest return this year by a US stock in the Pharmaceuticals Industry, returning 723.1%.

ASSET	YEAR	% RETURN
Relmada Therapeutics (RLMD)	2025	723.05%
Terns Pharmaceuticals (TERN)	2025	388.65%
Ventyx Biosciences (VTYX)	2025	338.74%
Nektar Therapeutics (NKTR)	2025	310.9%
Sol Gel Technologies (SLGL)	2025	272.63%
Amylyx Pharmaceuticals (AMLX)	2025	268.07%
Alto Neuroscience (ANRO)	2025	243.02%
NovaBay Pharmaceuticals (NBY)	2025	176.92%
Trevi Therapeutics (TRVI)	2025	173.19%
Liquidia Technologies (LQDA)	2025	155.72%
Talphera (TLPH)	2025	152.83%
Evoke Pharma (EVOK)	2025	122.71%
Avadel Pharmaceuticals (AVDL)	2025	117.65%
Xeris Pharmaceuticals (XERS)	2025	108.85%
Maze Therapeutics, Inc Common Stock (MAZE)	2025	107.69%
Phibro Animal Health (PAHC)	2025	107.15%
Fulcrum Therapeutics (FULC)	2025	102.71%
Theravance Biopharma (TBPH)	2025	95.45%
Eyepoint Pharmaceuticals (EYPT)	2025	83.93%
Phathom Pharmaceuticals (PHAT)	2025	83.37%
Elanco Animal Health (ELAN)	2025	75.04%
Axsome Therapeutics (AXSM)	2025	73%
Elicio Therapeutics (ELTX)	2025	72.43%
Aquestive Therapeutics (AQST)	2025	64.17%
TherapeuticsMD (TXMD)	2025	64%